title: Efficacy and safety of adalimumab in ankylosing spondylitis.
abstract: Ankylosing spondylitis (AS) is the most common and most severe subtype of spondyloarthritis. It also may be an outcome of any of the other spondyloarthritis subtypes. AS preferentially affects the sacroiliac joints and the tip of the column, with a tendency to later ankylosis. Peripheral joints, enthesis, and other extra-articular involvement may be observed. Tumor necrosis factor (TNF) inhibitors are now well-established, effective drugs in the treatment of AS symptoms. Adalimumab, which is a fully human monoclonal antibody that binds to and neutralizes TNF, has demonstrated efficacy in treating AS symptoms, including axial involvement, peripheral arthritis, enthesitis, uveitis, gut involvement, and psoriasis. Furthermore, adalimumab has showed an overall acceptable safety profile. In this paper, we review the efficacy and safety profile of adalimumab in the treatment of AS, and discuss its differences from the other anti-TNF drugs reported in the literature.
authors: Rheumatology Department, Military Hospital Mohammed V, Rabat, Morocco.
authors: Aziza
authors: A
authors: Mounach
authors: Rheumatology Department, Military Hospital Mohammed V, Rabat, Morocco.
authors: Abdellah
authors: A
authors: El Maghraoui
keywords: adalimumab; ankylosing spondylitis; spondyloarthritis; tumor necrosis factor-α